Limited contribution of humoral immunity to the clearance of measles viremia in rhesus monkeys

Journal of Infectious Diseases

Volumn 190, Issue 5, 2004, Pages 998-1005

  Permar, Sallie R ^a,b   Klumpp, Sherry A ^a   Mansfield, Keith G ^a   Carville, Angela A L ^a   Gorgone, Darci A ^a   Lifton, Michelle A ^a   Schmitz, Jörn E ^a   Reimann, Keith A ^a   Polack, Fernando P ^b   Griffin, Diane E ^b   Letvin, Norman L ^a,c  

^a HARVARD MEDICAL SCHOOL   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIBODY; CD20 ANTIGEN; CD8 ANTIGEN; MONOCLONAL ANTIBODY; OKT 8;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CONTROLLED STUDY; DISEASE DURATION; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOCYTE DEPLETION; MEASLES; MEASLES VIRUS; NONHUMAN; PRIORITY JOURNAL; RASH; RHESUS MONKEY; T LYMPHOCYTE; VIREMIA; VIRUS REPLICATION;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, VIRAL; ANTIBODY FORMATION; ANTIGENS, CD20; B-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; DISEASE MODELS, ANIMAL; HUMANS; LYMPHOCYTE DEPLETION; MACACA MULATTA; MEASLES; MEASLES VIRUS; VIREMIA;

EID: 4344701083     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/422846     Document Type: Article

References (33)

1. Gans HA, Arvin AM, Galinus J, Logan L, DeHovitz R, Maldonado Y. Deficiency of the humoral immune response to measles vaccine in infants immunized at age 6 months. JAMA 1998; 280:527-32.
2. Burnet FM. Measles as an index of immunological function. Lancet 1968; 2:610-3.
3. Good RA, Zak SJ. Disturbance in gamma globulin synthesis as experiments of nature. Pediatrics 1956; 18:109-49.
4. Kaplan LJ, Daum RS, Smaron M, McCarthy CA. Severe measles in immunocompromised patients. JAMA 1992; 267:1237-41.
5. + lymphocytes in control and clearance of measles virus infection of rhesus monkeys. J Virol 2003; 77:4396-400.
6. Chen RT, Markowitz LE, Albrecht P, et al. Measles antibody: reevaluation of protective titers. J Infect Dis 1990; 162:1036-42.
7. Feldman HA, Novack A, Warren J, Haute T. Inactivated measles virus vaccine. II. Prevention of natural and experimental measles with the vaccine. JAMA 1962; 179:391-7.
8. Fulginiti V, Kempe CH. Measles exposure among vaccine recipients. Amer J Dis Child 1963; 106:62-73.
9. Auwaerter PG, Rota PA, Elkins WR, et al. Measles virus infection in rhesus macaques: altered immune responses and comparison of the virulence of six different virus strains. J Infect Dis 1999; 180:950-8.
10. Polack FP, Lee SH, Permar S, et al. Successful DNA immunization against measles: neutralizing antibody against either the hemagglutinin or fusion glycoprotein protects rhesus macaques without evidence of atypical measles. Nat Med 2000; 6:776-81.
11. Premenko-Lanier M, Rota PA, Rhodes G, et al. DNA vaccination of infants in the presence of maternal antibody: a measles model in the primate. Virology 2003; 307:67-75.
12. Kobune F, Sakata H, Sugiura A. Marmoset lymphoblastoid cells as a sensitive host for isolation of measles virus. J Virol 1990; 64:700-5.
13. + lymphocytes. Science 1999; 283:857-60.
14. Schmitz JE, Kuroda MJ, Santra S, et al. Effect of humoral immune responses on controlling viremia during primary infection of rhesus monkeys with simian immunodeficiency virus. J Virol 2003; 77:2165-73.
15. Fujinami RS, Oldstone MB. Alterations in expression of measles virus polypeptides by antibody: molecular events in antibody-induced antigenic modulation. J Immunol 1980; 125:78-85.
16. Fujinami RS, Oldstone MB. Antiviral antibody reacting on the plasma membrane alters measles virus expression inside the cell. Nature 1979; 279:529-30.
17. Goldman MB, O'Bryan TA, Buckthal DJ, Tetor LM, Goldman JN. Suppression of measles virus expression by noncytolytic antibody in an immortalized macrophage cell line. J Virol 1995; 69:734-40.
18. Schneider-Schaulies S, Liebert UG, Segev Y, Rager-Zisman B, Wolfson M, ter Meulen V. Antibody-dependent transcriptional regulation of measles virus in persistently infected neural cells. J Virol 1992; 66:5534-41.
19. Forthal DN, Landucci G, Habis A, Zartarian M, Katz J, Tilles JG. Measles virus-specific functional antibody responses and viremia during acute measles. J Infect Dis 1994; 169:1377-80.
20. Endo A, Izumi H, Miyashita M, Taniguchi K, Okubo O, Harada K. Current efficacy of postexposure prophylaxis against measles with immunoglobulin. J Pediatr 2001; 138:926-8.
21. Janeway CA. Use of concentrated human serum gamma globulin in the prevention and attenuation of measles. Bull NY Acad Med 1945; 21:202-22.
22. Permar SR, Moss WJ, Ryon JJ, et al. Prolonged measles virus shedding in human immunodeficiency virus-infected children, detected by reverse transcriptase-polymerase chain reaction. J Infect Dis 2001; 183:532-8.
23. Kimura A, Tosaka K, Nakao T. Measles rash. I. Light and electron microscopic study of skin eruptions. Arch Virol 1975; 47:295-307.
24. Moss WJ, Monze M, Ryon JJ, Quinn TC, Griffin DE, Cutts F. Prospective study of measles in hospitalized, human immunodeficiency virus (HIV)-infected and HIV-uninfected children in Zambia. Clin Infect Dis 2002; 35:189-96.
25. Polack FP, Auwaerter PG, Lee SH, et al. Production of atypical measles in rhesus macaques: evidence for disease mediated by immune complex formation and eosinophils in the presence of fusion-inhibiting antibody. Nat Med 1999; 5:629-34.
26. Guinee VF, Henderson DA, Casey HL, et al. Cooperative measles vaccine field trial. I. Clinical efficacy. Pediatrics 1966; 37:649-65.
27. Baba TW, Liska V, Hofmann-Lehmann R, et al. Human neutralizing monoclonal antibodies of the IgG1 subtype protect against mucosal simian-human immunodeficiency virus infection. Nat Med 2000; 6:200-6.
28. Mascola JR, Lewis MG, Stiegler G, et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J Virol 1999; 73:4009-18.
29. Mascola JR, Stiegler G, VanCott TC, et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat Med 2000; 6:207-10.
30. Nishimura Y, Igarashi T, Haigwood N, et al. Determination of a statistically valid neutralization titer in plasma that confers protection against simian-human immunodeficiency virus challenge following passive transfer of high-titered neutralizing antibodies. J Virol 2002; 76:2123-30.
31. Parren PW, Marx PA, Hessell AJ, et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J Virol 2001; 75:8340-7.
32. Mondelli M, Vergani GM, Alberti A, et al. Specificity of T lymphocyte cytotoxicity to autologous hepatocytes in chronic hepatitis B virus infection: evidence that T cells are directed against HBV core antigen expressed on hepatocytes. J Immunol 1982; 129:2773-8.
33. Szmuness W, Stevens CE, Harley EJ, et al. Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States. N Engl J Med 1980; 303:833-41.